NCT03626714View on ClinicalTrials.gov

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

January 5, 2019

Study Completion Date

January 5, 2019

Conditions
Organ Transplant RejectionPsoriasis
Interventions
DRUG

Sustained Release Injectable Tacrolimus

Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Auritec Pharmaceuticals

INDUSTRY

NCT03626714 - Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study | Biotech Hunter | Biotech Hunter